¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibiotics, peptide"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® peptide ÇÑ±Û ÆéƼµå
¼³¸í   
  µÎ °³ÀÌ»óÀÇ ¾Æ¹Ì³ë»ê ºÐÀÚ »çÀÌ¿¡¼­, ÇÑÂÊÀÇ ¾Æ¹Ì³ë±â¿Í ´Ù¸¥ ÂÊÀÇ Ä«¸£º¹½Ç±â°¡ ¹° ºÐÀÚ¸¦ ÀÒÀ¸¸é¼­ ÃàÇÕÇÏ¿© ÀÌ·ç´Â ¾Æ¹Ìµå °áÇվƹ̳ë»êÀÇ ¼ö°¡ 2, 3, ¡¦ ÀΠ°æ¿ì, °¢°¢ µðÆéƼµå, Æ®¸®ÆéƼµå, ¡¦µîÀ¸·Î ºÎ¸£¸ç, ¿©·¯ °³ÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ±¸¼ºµÇ´Â °ÍÀ» ¿Ã¸®°íÆéƼµå, À̺¸´Ù Å« °ÍÀ» Æú¸®ÆéƼµå¶ó°í ÇÑ´Ù. Á÷¼â»óÀÇ °ÍÀÌ ¸¹Áö¸¸, È¯»ó ±¸Á¶¸¦ °®´Â ÆéƼµåµµ ÀÖ´Ù. ÀúºÐÀÚÀÇ ÆéƼµå´Â ¹°, »ê, ¾ËÄ®¸® µûÀ§¿¡ Àß ³ì°í ¾ËÄڿÿ¡´Â ³ìÁö ¾ÊÀ¸³ª, °íºÐÀÚÀÇ ÆéƼµå´Â ¹°¿¡ Àß ³ìÁö ¾Ê°í ´Ü¹éÁú°ú ¼ºÁúÀÌ ºñ½ÁÇÏ´Ù. ³úÇϼöüȣ¸£¸ó, ºê¶óµðŰ´Ñ µî°ú °°ÀÌ »ý¸®Àû±â´ÉÀÌ ÇöÀúÇÑ °ÍÀº »ý¸®È°¼ºÆéƼµå(bioactive peptide)¶ó°í ÇÑ´Ù.
¿µ¹® antibiotics ÇÑ±Û Ç×»ýÁ¦
¼³¸í   
  ¹Ì»ý¹°ÀÌ ¸¸µé¾î³»´Â Ç×»ý ¹°Áú·Î µÈ ¾àÁ¦. ´Ù¸¥ ¹Ì»ý¹°À̳ª »ý¹° ¼¼Æ÷¸¦ ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦Çϰųª Á×ÀδÙ. ¹Ì»ý¹°¿¡ ÀÇÇØ »ý»êµÇ¸ç ¹Ì»ý¹°ÀÇ ¹ßÀ° ¶Ç´Â ¾Ç¼ºÁ¾¾çÀÇ Áõ½ÄÀ» ÀúÁöÇϴ ¹°ÁúÀÌ´Ù. ¼÷ÁÖ¿¡ ¹«ÇØÇÑ Ç×»ý¹°ÁúÀº »ç¶÷-µ¿¹°-½Ä¹°ÀÇ ¼¼±Õ°¨¿°ÁõÀÇ Ä¡·á¿¡ È­Çпä¹ýÁ¦·Î »ç¿ëÇÑ´Ù. ±× ÀÛ¿ë¸ÞÄ¿´ÏÁòÀº ¹Ì»ý¹°ÀÇ ¼¼Æ÷º®À» ÇÕ¼ºÇϴ °ÍÀ» ÀúÇØÇϴ °Í, ÇÙ»ê(DNA, RNA) ÇÕ¼ºÀúÇØ, ´Ü¹éÁú ÇÕ¼ºÀúÇØ, º¸È¿¼ÒÇÕ¼ºÀúÇØ µîÀÌ ÀÖ´Ù. ÀÛ¿ë¸ÞÄ¿´ÏÁò°ú È­Çб¸Á¶¿¡ µû¶ó ¥â-¶ôްè(Æä´Ï½Ç¸°·ù), ¾Æ¹Ì³ë´ç·ù°è, Åׯ®¶ó»çÀÌŬ¸°°è, Å¬·Î¶÷Æä´ÏÄݰè, Æú¸®ÆéƼµå°è, ±âŸ(¸°ÄÚ¸¶À̽Å, ¹ÝÄÚ¸¶À̽еî)·Î ºÐ·ùµÈ´Ù. Ç×Á¾¾çÇ×»ý¹°Áú¿¡´Â ¾Æµå¸®¾Æ¸¶À̽Å, ¾ÇƼ³ë¸¶À̽ÅD, ¸¶ÀÌÅ丶À̽ÅC, ºí·¹¿À¸¶À̽еîÀÌ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atrial natriuretic peptide
    ½É¹æ³ªÆ®·ýÀÌ´¢ÆéƼµå
  • brain natriuretic peptide
    ³ú³ªÆ®·ýÀÌ´¢ÆéƼµå
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • gastrin-releasing peptide
    °¡½ºÆ®¸°À¯¸®ÆéƼµå
  • glucagon-like insulinotropic peptide
    ±Û·çÄ«°ïÀ¯»çÀν¶¸°ÀÚ±ØÆéÆ¼µå
  • glucagon-like peptide
    ±Û·çÄ«°ïÀ¯»çÆéƼµå
  • peptide
    ÆéƼµå
  • peptide bond
    ÆéƼµå°áÇÕ
  • peptide linkage
    ÆéƼµå°áÇÕ
  • signal peptide
    ½ÅÈ£ÆéƼµå
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peptide
    ÆéƼµå
  • atrial natriuretic peptide
    ½É¹æ³ªÆ®·ýÀÌ´¢ÆéƼµå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • brain natriuretic peptide
    ³ú³ªÆ®·ýÀÌ´¢ÆéƼµå
  • peptide bond
    ÆÕƼµå°áÇÕ
  • gastrin-releasing peptide
    °¡½ºÆ®¸°À¯¸®ÆéƼµå
  • peptide linkage
    ÆéƼµå°áÇÕ
  • peptide
    ÆéƼµå
  • signal peptide
    ½ÅÈ£ÆéƼµå
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibiotics
    Ç×»ýÁ¦(ù÷ßæð¥)
  • BNP=> brain natriuretic peptide
    ³ú ³ªÆ®·ý ÀÌ´¢ ÆéƼµå
  • GIP (Gastric inhibitory peptide)
    À§Àå¾ïÁ¦(êÖíóåäð¤) ÆéŸÀ̵å
  • GRP (Gastrin-releasing peptide)
    °¡½ºÆ®¸°-ºÐºñÆéÆÄÀ̵å
  • Gastric inhibitory peptide
    À§¾ïÁ¦(êÖåäð¤)È£¸£¸ó
  • Gastrin-releasing peptide
    °¡½ºÆ®¸°ºÐºñÆéŸÀ̵å
  • VIP : vasoactive intestinal peptide
    Ç÷°üÀÛ¿ë ¼ÒÀåÆéŸÀ̵å.
  • VIP = vasoactive intestinal (poly)peptide
    Ç÷°üÀۿ뼺 ÀåÆéƼµå
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peptide antibiotics
    ÆÕƼµåÇ×»ýÁ¦
  • antibiotics
    Ç×»ýÁ¦(ù÷ßæð¥)
  • bacteriostatic antibiotics
    Á¤±Õ¼º Ç×»ý¹°Áú(¡­àõù÷ßæÚªòõ).
  • beta-lactam antibiotics
    º£Å¸-¶ôŽÇ×»ýÁ¦.
  • intestinal antibiotics
    Àå°ü¿ë Ç×»ý¹°Áú(íóηéÄ ù÷ßæÚªòõ).
  • intestinal antibiotics
    Àå°ü¿ë Ç×»ý¹°Áú(íóηéÄù÷ßæÚªòõ).
  • prophylactic antibiotics
    ¿¹¹æÀû Ç×»ýÁ¦
  • resistance to antibiotics
    Ç×»ýÁ¦ÀúÇ×¼º(ù÷ßæð¥î½ù÷àõ), Ç×»ýÁ¦³»¼º(ù÷ßæð¥ Ò±àõ).
  • atrial natriuretic peptide
    ½É¹æ³ªÆ®·ýÀÌ´¢ÆéŸÀ̵å, ½É¹æ³ªÆ®·ýÀÌ´¢ÆéƼµå
  • brain gut peptide
    ³úÀå °üÆéƼµå.
  • brain gut peptide
    ³úÀå °üÆéƼµå.
  • brain gut peptide
    ³úÀå°üÆéƼµå
  • brain natriuretic peptide
    ³ú ³ªÆ®·ý ÀÌ´¢ ÆéƼµå
  • brain peptide
    ³úÆéƼµå.
  • c-peptide
    ¾¾-ÆéŸÀ̵å, ¾¾-ÆéƼµå
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • aminoglycoside antibiotics
    ¾Æ¹Ì³ë±Û¶óÀÌÄÚ»çÀ̵å Ç×»ýÁ¦(ù÷ßæð¥)
  • antitumor antibiotics
    Ç×Á¾¾ç Ç×»ýÁ¦(ù÷ðþåËù÷ßæð¥)
  • beta lactam antibiotics
    º£Å¸ ¶ôŽ Ç×»ýÁ¦(ù÷ßæð¥)
  • depsipeptide antibiotics
    µª½ÃÆéŸÀ̵å Ç×»ýÁ¦(ù÷ßæð¥)
  • ion-translocating antibiotics
    ÀÌ¿ÂÀüÀ§ Ç×»ýÁ¦(ï®êÈù÷ßæð¥)
  • purine antibiotics
    Ç»¸° Ç×»ýÁ¦(ù÷ßæð¥)
  • pyrimidine antibiotics
    ÇǸ®¹Ìµò Ç×»ýÁ¦(ù÷ßæð¥)
  • connecting peptide
    ¿¬°á(Ö§Ì¿) ÆéŸÀ̵å
  • C peptide
    C ÆéŸÀ̵å
  • cyclic peptide
    °í¸®ÆéŸÀ̵å
  • DFP peptide
    DEP ÆéŸÀ̵å
  • fast peptide liquid chromatography
    °í¼Ó(ÍÔáÜ) ÆéŸÀÌµå ¾×ü(äûô÷)Å©·Î¸¶Åä±×·¡ÇÇ
  • gastric inhibitory peptide
    À§(êÖ) ÀúÇØ(îÁúª) ÆéŸÀ̵å
  • leader peptide
    ¼±µµ(à»Óô) ÆéŸÀ̵å
  • leader sequence peptide
    ¼±µµ¼­¿­(à»ÓôßíÖª) ÆéŸÀ̵å
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • broadsoectrum antibiotics
    ±¤¹üÀ§Ç×»ýÁ¦
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TEF Tracheo-Esophageal Fistula
  ? Tx
    1. Infant Warmer
 ...
NOABX no antibiotics
ORALABX oral antibiotics
C-Peptide Connecting Peptide
ERP early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AGs Aminoglycoside antibiotics
AB Antibiotics
C-peptide connecting peptide
LAP 1-latency associated peptide
GLP-1 1.Glucagon-like peptide-1 amide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • aminoglycoside antibiotics
    ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵å Ç×»ýÁ¦
    ½ºÅ×·¾Å丶À̽Å, °¡³ª¸¶À̽Å, °ÕŸ¸¶À̽Å, ¾Æ¹ÌÄ«½Å, Åäºê¶ó¸¶À̽еîÀÌ ÀÖ´Ù. ±¤¹üÀ§ Ç×±Õ ½ºÆåÆ®·³À» Áö´Ï°í ±×¶÷ À½¼º °£±Õ¿¡ ´ëÇØ¼­µµ È¿°úÀûÀÌ´Ù. ƯÈ÷ Ç׻꼺 ±Õ¿¡ È¿°úÀûÀ̰í PAS³ª INAH¿Í º´¿ëÇØ¼­ Ä¡·á¿¡ »ç¿ëµÈ´Ù.
  • antibiotics
    Ç×»ýÁ¦
    ¾î¶² »ý¹° ȤÀº ¹Ì»ý¹°¿¡¼­ »ý¼ºµÇ´Â ¹°Áú·Î¼­ ´Ù¸¥ ¹Ì»ý¹°ÀÇ ¼ºÀå ¹× ¹ßÀ°À» ¾ïÁ¦ ȤÀº »ç¸ê½ÃŰ´Â ¹°Áú. ¼÷ÁÖ¿¡ ¹«ÇØÇÑ È¯°æ ¹°ÁúÀº »ç¶÷, µ¿¹°, ½Ä¹°ÀÇ ¼¼±Õ °¨¿°Áõ Ä¡·áÀÇ È­Çпä¹ýÁ¦·Î »ç¿ëµÈ´Ù.
  • bacteriostatic antibiotics
    Á¤±Õ¼º Ç×»ý ¹°Áú
    ¼¼±ÕÀÇ ¹ßÀ°, Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â È¿°ú°¡ ÀÖ´Â Ç×»ý ¹°Áú.
  • beta-lactam antibiotics
    º£Å¸-¶ôŽ Ç×»ýÁ¦
  • broad spectrum antibiotics
    ±¤¹üÀ§ Ç×»ýÁ¦, ±¤¿ª Ç×»ýÁ¦
  • chloramphenicol group antibiotics
    Ŭ·Î¶÷Æä´ÏÄݱº Ç×»ýÁ¦
  • intestinal antibiotics
    Àå°ü¿ë Ç×»ý ¹°Áú
  • PCN-resistant-lactam antibiotics

    PDGF (Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ

  • 9-amino acid peptide
    9-¾Æ¹Ì³ë»ê ÆéŸÀ̵å
  • brain peptide
    ³ú ÆéƼµå
  • corticotropin-like intermediate lobe peptide

    corticotropin-releasing factor (ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ¿ä¼Ò, ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ÀÎÀÚ

  • dynorphin-related peptide
    ´ÙÀ̳îÇÉ °ü·Ã ÆéƼµå
  • endogenous analgesic peptide system
    ³»¿ø¼º ÁøÅ뼺 ÆéƼµå°è
  • endogenous opiate peptide
    ³»Àμº ¾ÆÆí ÆéŸÀ̵å, ³»À缺 ¿ÀÇÇ¿¡ÀÌÆ® ÆÕŸÀ̵å, ³»À缺 ¾ÆÆí¾ç ÆéŸÀ̵å
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
antibiotics, peptide Antibiotics whose structure contains one or more peptides, usually cyclic. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
antibiotics Drugs that fight infections.
(12 Dec 1998)
antibiotics, aminoglycoside Antibiotics whose structure contains amino sugars attached to an aminocyclitol ring (hexose nucleus) by glycosidic bonds. Aminoglycoside antibiotics are derived from various species of streptomyces and micromonospora or are produced synthetically. They act by inhibiting protein synthesis.
(12 Dec 1998)
antibiotics, anthracycline Antibiotics which have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to a sugar molecule. These antibiotics have potent antineoplastic activity. The two best known members of this group are daunorubicin and doxorubicin. Since these agents intercalate with DNA, many DNA functions are adversely affected. Futhermore they interact with cell membranes thereby altering their functions and also generate hydrogen peroxide and hydroxy radicals which are highly destructive to cells.
(12 Dec 1998)
antibiotics, antifungal Antibiotics inhibiting the growth of or killing fungi and used in the treatment of various fungal diseases.
(12 Dec 1998)
antibiotics, antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the development of neoplasms.
(12 Dec 1998)
antibiotics, antitubercular Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic.
(12 Dec 1998)
antibiotics, combined Combination of antibiotics used against difficult-to-treat infections. Antibiotic combinations have been used mainly to broaden the antibacterial spectrum and prevent development of resistance. In some instances these combinations have shown lower toxicity, but drug antagonism may be one of the problems encountered by their use. They may be given simultaneously or sequentially. The drugs need not be in the same dosage form.
(12 Dec 1998)
antibiotics, glycopeptide Antibiotics whose structure contains one or more cyclic peptides to which are attached one or more deoxy sugars in glycosidic linkage. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls.
(12 Dec 1998)
antibiotics, lactam Compounds containing a four-membered ring with an amide nitrogen and a keto group. This configuration includes bacteriostatic, cell-wall inhibiting antibiotics, such as penicillins and cephalosporins; their analogs and derivatives, such as the penem (or penam) compounds; clavulanic acids; and monobactams. They are substrates for and may act as inhibitors of bacterial beta-lactamases.
(12 Dec 1998)
antibiotics, macrolide A group of antibiotics containing a macrocyclic lactone ring linked glycosidically to one or more sugar moieties. These antibiotics are produced by certain species of streptomyces. They often inhibit protein synthesis by binding to the 50s subunits of 70s ribosomes.
(12 Dec 1998)
antibiotics, tetracycline <chemical> Broad-spectrum natural and semisynthetic antibiotics with a naphthacene structure obtained from various streptomyces species.
Pharmacological action: protein synthesis inhibitor.
(12 Dec 1998)
intravenous antibiotics The administration of an antibiotic solution into the venous circulation.
(27 Sep 1997)
topical antibiotics A ointment (or cream) based medication that kills bacteria.
Examples include Neosporin, Bactroban, Garamycin, bacitracin, gentamicin, mupirocin, neomycin, silver sulphasalazine, chloramphenicol and clindamycin.
(27 Sep 1997)
alpha-aminoacyl-peptide hydrolases <enzyme> Registry number: EC 3.4.11.
(12 Dec 1998)
anionic neutrophil activating peptide <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes.
It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4.
Acronym: IL-8
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peptide
    ÆéŸÀ̵å;µÑ ÀÌ»óÀÇ ¾Æ¹Ì³ë»ê °áÇÕ¹°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á